Drug Trial Radar · NCT05321316
Nectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
May 31, 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Peking University Cancer Hospital & InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 11, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the ability of \[68Ga\]NT-CBH to detect nectin-4 overexpression in subjects with urinary system cancers, breast cancer, lung cancer, pancreatic cancer, gastrointestinal cancer, and ovarian cancer.
Conditions
- Urothelial Carcinoma
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Gastrointestinal Cancers
- Ovarian Cancer
Interventions
18F-FDGDrug
All study participants will undergo one 18F-FDG PET/CT scan.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Standardized uptake value(SUV)Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.